1334313-67-5

Basic information

• Product Name: (S)-1-(tert-butoxycarbonyl)-3,3-diMethyl-1,3-azasilolidine-5-carboxylic acid
• Synonyms: (S)-1-(tert-butoxycarbonyl)-3,3-diMethyl-1,3-azasilolidine-5-carboxylic acid;(5S)-1-[(tert-butoxy)carbonyl]-3,3-dimethyl-1,3-azasilolidine-5-carboxylic acid
• CAS NO: 1334313-67-5
• Molecular Formula: C₁₁H₂₁NO₄Si
• Molecular Weight: 259.37424
• Mol File: 1334313-67-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-1-(tert-butoxycarbonyl)-3,3-diMethyl-1,3-azasilolidine-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(tert-butoxycarbonyl)-3,3-diMethyl-1,3-azasilolidine-5-carboxylic acid(1334313-67-5)
• EPA Substance Registry System: (S)-1-(tert-butoxycarbonyl)-3,3-diMethyl-1,3-azasilolidine-5-carboxylic acid(1334313-67-5)

Safety Data

• Hazardous Substances Data: 1334313-67-5(Hazardous Substances Data)

Usage

General Description

(S)-1-(tert-butoxycarbonyl)-3,3-dimethyl-1,3-azasilolidine-5-carboxylic acid is a chemical compound that belongs to the class of azasilolidine-5-carboxylic acid derivatives. It is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals. The compound possesses a tert-butoxycarbonyl group, which provides protection for the amine functionality, allowing for selective reactions at other sites of the molecule. The presence of the azasilolidine ring imparts unique structural and electronic properties that make it suitable for use in diverse synthetic applications. Additionally, the compound's 3,3-dimethyl substituents contribute to its stability and enhance its reactivity in certain reactions. Overall, (S)-1-(tert-butoxycarbonyl)-3,3-dimethyl-1,3-azasilolidine-5-carboxylic acid is a versatile and valuable intermediate in organic synthesis.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 415898-69-0 C₆H₁₃NO₂Si 
• 1334313-65-3 (2R,5R)-2-[(chloromethyl-dimethyl-silanyl)-methyl]-5-isopropyl-3,6-dimethoxy-2,5-dihydro-pyrazine 

Relevant articles and documents

Novel cilengitide-based cyclic RGD peptides as αvβ3 integrin inhibitors

In this letter, we report a series of five new RGD-containing cyclic peptides as potent inhibitors to αvβ3 integrin protein. We have incorporated various unnatural lipophilic amino acids into the cyclic RGD framework of cilengitide, which is selective for αvβ3 integrin. All the newly synthesized cyclic peptides were evaluated in vitro solid phase binding assay and investigated for their binding behaviour towards integrin subtypes. All the cyclic peptides were synthesized in excellent yield following solution-phase coupling strategy. The cyclic RGD peptides 1a-e exhibited IC50 of 9.9, 5.5, 72, 11 and 3.3 nM, respectively, towards αvβ3 integrin protein. This finding offers further opportunities for the introduction unusual amino acids into the cyclic peptide framework of cilengitide.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.